These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17546776)

  • 1. [Overview of enzyme replacement therapy in mucopolysaccharidosis].
    Fouilhoux A; Guffon N
    Presse Med; 2007 Mar; 36 Spec No 1():1S96-9. PubMed ID: 17546776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme replacement therapy for the management of the mucopolysaccharidoses.
    Wraith JE
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S63-5. PubMed ID: 20040314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy for the mucopolysaccharidoses.
    Valayannopoulos V; Wijburg FA
    Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v49-59. PubMed ID: 22210671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses.
    Muenzer J
    Mol Genet Metab; 2014 Feb; 111(2):63-72. PubMed ID: 24388732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
    Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
    Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Enzyme replacement therapy of lysosomal storage diseases].
    Germain DP; Boucly C; Carlier RY; Caudron E; Charlier P; Colas F; Jabbour F; Martinez V; Mokhtari S; Orlikowski D; Pellegrini N; Perronne C; Prigent H; Rubinsztajn R; Benistan K
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S279-91. PubMed ID: 21211680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rapid cessation of enzyme replacement therapy: a report of 5 more cases.
    Jurecka A; Malinova V; Tylki-Szymańska A
    Mol Genet Metab; 2014 Feb; 111(2):212-3. PubMed ID: 24060239
    [No Abstract]   [Full Text] [Related]  

  • 8. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
    Brunelli MJ; Atallah ÁN; da Silva EM
    Cochrane Database Syst Rev; 2016 Mar; 3():CD009806. PubMed ID: 26943923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective chart review of urinary glycosaminoglycan excretion and long-term clinical outcomes of enzyme replacement therapy in patients with mucopolysaccharidoses.
    Jones SA; Marsden D; Koutsoukos T; Sniadecki J; Tylee K; Phillippo S; Kakkis E
    Mol Genet Metab; 2020 Aug; 130(4):255-261. PubMed ID: 32563631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders.
    Miebach E
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S100-6. PubMed ID: 20040319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): experience in Hong Kong.
    But WM; Wong MY; Chow JC; Chan WK; Ko WT; Wu SP; Wong ML; Miu TY; Tse WY; Hung WW; Fan TW; Shek CC
    Hong Kong Med J; 2011 Aug; 17(4):317-24. PubMed ID: 21813902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease.
    Di Natale P; Villani GR; Parini R; Scarpa M; Parenti G; Pontarelli G; Grosso M; Sersale G; Tomanin R; Sibilio M; Barone R; Fiumara A
    Biotechnol Appl Biochem; 2008 Mar; 49(Pt 3):219-23. PubMed ID: 17672828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program.
    Harmatz PR; Lampe C; Parini R; Sharma R; Teles EL; Johnson J; Sivam D; Sisic Z
    J Inherit Metab Dis; 2019 May; 42(3):519-526. PubMed ID: 30834539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy for mucopolysaccharidosis VI--experience in Taiwan.
    Lin HY; Chen MR; Chuang CK; Chen CP; Lin DS; Chien YH; Ke YY; Tsai FJ; Pan HP; Lin SJ; Hwu WL; Niu DM; Lee NC; Lin SP
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S421-7. PubMed ID: 20924685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
    Muenzer J; Gucsavas-Calikoglu M; McCandless SE; Schuetz TJ; Kimura A
    Mol Genet Metab; 2007 Mar; 90(3):329-37. PubMed ID: 17185020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.
    Harmatz P; Giugliani R; Schwartz I; Guffon N; Teles EL; Miranda MC; Wraith JE; Beck M; Arash L; Scarpa M; Yu ZF; Wittes J; Berger KI; Newman MS; Lowe AM; Kakkis E; Swiedler SJ;
    J Pediatr; 2006 Apr; 148(4):533-539. PubMed ID: 16647419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures.
    Harmatz P
    Turk J Pediatr; 2010; 52(5):443-9. PubMed ID: 21434527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Desensitization Method to Maintain Enzyme Replacement Therapy in Mucopolysaccharidosis Type VI.
    Kör D; Şeker Yilmaz B; Bulut FD; Önenli Mungan N; Ufuk Altıntaş D
    J Investig Allergol Clin Immunol; 2016; 26(2):130-2. PubMed ID: 27164636
    [No Abstract]   [Full Text] [Related]  

  • 20. Glycosaminoglycans can be associated with oxidative damage in mucopolysaccharidosis II patients submitted to enzyme replacement therapy.
    Negretto GW; Deon M; Biancini GB; Burin MG; Giugliani R; Vargas CR
    Cell Biol Toxicol; 2014 Aug; 30(4):189-93. PubMed ID: 25022704
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.